WFDC2 and endometrial carcinoma: The results of our study showed that the ANXA2 and HE4 expression in stage III–IV endometrial carcinoma patients was higher than stage I–II patients (Table 2), which was correlated with FIGO staging and the prognosis of survival in patients with endometrial carcinoma (Table 3), as further supported by studies investigating the role of ANXA2 and HE4 in other tumors [30–33].